Emerging Pathways and Promising Agents with Possible Disease Modifying Effect in Osteoarthritis Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|15|6|635-661

ISSN： 1389-4501

Source： Current Drug Targets, Vol.15, Iss.6, 2014-06, pp. : 635-661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

By Phillips C.J.  

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 561-574

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 512-519

Bentham Science Publishers

Access to resources Recommend Favorite

Cytokines and Growth Factors in the Treatment of Osteoarthritis: What Could be the Best Disease Modifying Drugs

By  

Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, Vol. 4, Iss. 3, 2005-06 ,pp. : 235-249

Bentham Science Publishers

Access to resources Recommend Favorite

Licofelone a likely disease modifying therapy for osteoarthritis

By  

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Disease-Modifying Therapies for Osteoarthritis: Current Status

By Marc Fajardo   Paul E. Di Cesare  

Drugs & Aging, Vol. 22, Iss. 2, 2005-01 ,pp. : 141-161

Adis International

Access to resources Recommend Favorite